New hope for cervical cancer: drug combo targets tumors resistant to immunotherapy

NCT ID NCT05824468

Ongoing Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a combination of two drugs—zimberelimab (an immunotherapy) and lenvatinib (a targeted therapy)—in 30 patients with advanced cervical cancer that has worsened after prior immunotherapy. The goal is to see if the combo can shrink tumors or slow disease progression. Researchers are also checking safety and the best dose of lenvatinib.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zimberelimab (an immunotherapy drug) and lenvatinib (a targeted therapy drug)
What this could lead to: If successful, this combination could offer a new treatment option for advanced cervical cancer patients whose disease has worsened after prior immunotherapy.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The combination may cause significant side effects and may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER CERVICAL CARCINOMA

Contacts and locations

Locations

Sun Yat-sen University Cancer Cetntre

Guangzhou, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.